- Home
- QNCX vs XFOR Comparison
QNCX vs XFOR Comparison
Compare QNCX & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- XFOR
- Stock Information
- Founded
- QNCX 2012
- XFOR 2014
- Country
- QNCX United States
- XFOR United States
- Employees
- QNCX N/A
- XFOR N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QNCX Health Care
- XFOR Health Care
- Exchange
- QNCX Nasdaq
- XFOR Nasdaq
- Market Cap
- QNCX 90.8M
- XFOR 84.3M
- IPO Year
- QNCX 2019
- XFOR N/A
- Fundamental
- Price
- QNCX $1.60
- XFOR $3.26
- Analyst Decision
- QNCX Strong Buy
- XFOR Strong Buy
- Analyst Count
- QNCX 6
- XFOR 3
- Target Price
- QNCX $8.00
- XFOR $34.17
- AVG Volume (30 Days)
- QNCX 124.9K
- XFOR 1.6M
- Earning Date
- QNCX 11-12-2025
- XFOR 11-12-2025
- Dividend Yield
- QNCX N/A
- XFOR N/A
- EPS Growth
- QNCX N/A
- XFOR N/A
- EPS
- QNCX N/A
- XFOR N/A
- Revenue
- QNCX N/A
- XFOR $32,774,000.00
- Revenue This Year
- QNCX N/A
- XFOR $1,313.84
- Revenue Next Year
- QNCX N/A
- XFOR N/A
- P/E Ratio
- QNCX N/A
- XFOR N/A
- Revenue Growth
- QNCX N/A
- XFOR 5721.31
- 52 Week Low
- QNCX $0.69
- XFOR $1.35
- 52 Week High
- QNCX $2.45
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- QNCX 47.89
- XFOR 52.11
- Support Level
- QNCX $1.56
- XFOR $3.08
- Resistance Level
- QNCX $1.65
- XFOR $3.79
- Average True Range (ATR)
- QNCX 0.08
- XFOR 0.48
- MACD
- QNCX 0.00
- XFOR -0.10
- Stochastic Oscillator
- QNCX 64.65
- XFOR 13.07
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.